Infectious Disease


Research Update: Cytokine Storm Syndrome

September 28, 2020

Various drug therapies, including several cytokine blockers, are showing promise in addressing COVID-19 related cytokine storm syndrome, says Dr. Randall Cron of Children’s Hospital of Alabama.

Podcast: Making Sense of the COVID-19 Infodemic

August 13, 2020

Since the start of the COVID-19 pandemic early this year, there have been a number of studies published to test the effectiveness of hydroxychloroquine as a possible treatment. In today’s edition of Overdrive, the podcast from Rheumatology Network, Dr. Daniel Solomon, editor-in-chief of Arthritis and Rheumatology, helps us make sense of the science.

The COVID-19 Infodemic Simplified

August 07, 2020

In this week's news roundup and one-on-one interview, we talk with Dr. Daniel Solomon of Brigham and Women’s Hospital and editor-in-chief of the journal Arthritis and Rheumatology. Dr. Solomon and colleagues recently published a commentary called “The Infodemic of COVID-19” in which they break down the inundation of new science on hydroxychloroquine and the cytokine storm.

First COVID-19, then Kawasaki-like Disease in Children

July 24, 2020

Children with COVID-19 can develop pediatric, inflammatory multisystemic syndrome, or PIMS, which can lead to symptoms similar to that of a painful vasculitis condition called Kawasaki disease. Today we talk with Jagadeesh Bayry, Ph.D., and Caroline Galeotti, M.D., of the University of Paris who recently described in Nature Reviews Rheumatology related pediatric cases they saw in their clinic.

SpA Cases Flare Under COVID-19 Due to Misinformation

June 23, 2020

French researchers writing in Arthritis and Rheumatology report that of 609 surveyed spondyloarthritis patients self-isolating at home due to COVID-19, most say their condition has progressed while in isolation and for some, the change has been considerable.

EULAR COVID-19 Recommendations Say Continue Medications, but Vaccinate

June 09, 2020

EULAR has issued treatment recommendations for patients with rheumatic and musculoskeletal conditions with SARS-CoV-2 or COVID-19. A task force of 20 physicians settled on five overarching principles and 13 recommendations, which are similar to COVID-19 treatment guidelines issued by ACR in April-with slight variations.

COVID-19 and Rheumatic Disease Findings Reported at EULAR

June 05, 2020

COVID-19 was center-stage at this year's EULAR meeting. Dr. Pedro Machado, a rheumatologist with the University College London and chair of EULAR's Standing Committee for Epidemiology and Health Service Research shared the results of a study on patients with rheumatic disease who contracted COVID-19. He and his team found that patients taking a higher dose of prednisone, had an increased of being hospitalized. But patients receiving TNF blockers were less likely to be hospitalized. In this interview, Dr. Machado talks with us about the findings.

EULAR Report: Steroid Use Linked to More Severe COVID-19 Cases

June 04, 2020

Rheumatic disease patients treated with anti-TNF therapy and who contracted COVID-19, were hospitalized less often than patients treated with glucocorticoids, shows an observational study presented on Wednesday at the European Congress of Rheumatology (EULAR) annual meeting-which is being held virtually this week from the homes of more than 18,000 registered attendees.